InVitro International News Releases

InVitro International & the World's Animals Look Forward to 2026

Wed, 11 Feb 2026 09:00:00 -0500

Placentia, California--(Newsfile Corp. - February 11, 2026) - Today, InVitro International (OTCQB: IVRO) reported 1st Quarter FY '26 sales of $182,600, off 25% from the same period in FY '25. Net income of $10,604 fell 69% from the same period FY'25.Chairman & CEO, W. Richard Ulmer observed: "Our first quarter financials, though positive, do not reflect the many global Regulatory/Government statements encouraging in vitro testing over the past year. That acknowledged, we cannot recall in our 40...

Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains

Tue, 09 Dec 2025 09:00:00 -0500

Placentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of $878,937, up 8.3% over FY '24. Net income of $121,980 advanced 14.3% for the same period. CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the world announced they have already, or will soon, cease funding for animal testing; some have stopped now. Further, some RA's state OECD validated NON-animal...

IVRO's Q3 Packed with Positives; Sales, Profits, and U.S. Government/Global Support for Animal Welfare

Tue, 05 Aug 2025 09:00:00 -0400

Placentia, California--(Newsfile Corp. - August 5, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25, Q3 sales of $234,430, up 39.7% over the same period in FY '24. YTD sales of $675,080 are now 14.4% ahead of FY '24. Net income of $95,556 for three quarters in FY '25 is 17.1% ahead of the same three quarters in FY '24. CEO and Chairman, W. Richard Ulmer, expressed delight with IVRO's noteworthy progress: "In recent months we received quite a few new inquiries. Many are from...

IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances

Tue, 04 Feb 2025 09:00:00 -0500

Placentia, California--(Newsfile Corp. - February 4, 2025) - InVitro International (OTCQB: IVRO) today announced a solid 15.4% sales advance in Q1 of FY '25, totaling $244,143; this compares favorably to Q1 FY '24 sales of $211,625. FY '25 Q1 net income of $33,855 leapt 91.6% over the FY '24 Q1 figure of $17,667. InVitro International's CEO and acting President, W. Richard Ulmer said: "Together with our newly announced M & A activity in Europe, our team is pleased with FY '25 first Quarter...

IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization

Tue, 14 Jan 2025 09:00:00 -0500

Placentia, California--(Newsfile Corp. - January 14, 2025) - InVitro International (OTCQB: IVRO) previously revealed its strategic intent to accelerate organic growth by pursuing mergers and acquisitions. Today we are excited to announce our initial action to implement this strategy. InVitro International's Board of Directors unanimously approved a Memorandum of Understanding (MOU) to merge with a European based non-animal testing focused organization which has served their market for more than...

InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities

Wed, 04 Dec 2024 09:00:00 -0500

Placentia, California--(Newsfile Corp. - December 4, 2024) - Today InVitro International (OTCQB: IVRO) announced FY '24 sales of $811,290, up 2.4% vs. FY '23. Net income of $106,704 soared over the prior year's $1,555. Fourth quarter sales of $221,200 were 19.9% ahead of last year's same period while net income of $25,122 fell 48.8%, short of last year's 4th quarter, $49,035.While evaluating FY '24 financial results, CEO W. Richard Ulmer observed: "IVRO's Board of Directors is pleased with our...

InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan

Tue, 03 Sep 2024 09:00:00 -0400

Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the company. AKC will act in a business advising, investment banking, management and strategy role to support and advance IVRO's previously announced corporate growth plan. AKC will provide executive and organizational support, including strategy refinement, planning and operational review & more where...

InVitro International Progresses with Growth Strategies and Continues Profitability

Wed, 31 Jul 2024 09:00:00 -0400

Placentia, California--(Newsfile Corp. - July 31, 2024) - Today, InVitro International (OTCQB: IVRO) announced third quarter FY '24 sales of $167,850, off 16% vs the same quarter last year. Net income of $16,236 compared favorably with losses of $13,162 in the same quarter FY'23. Three quarters FY'24 sales of $590,090 were 3% off FY'23's total of $608,195; however, year to date earnings of $81,582 are 272% ahead of prior year losses of $47,480.IVRO CEO W. Richard Ulmer stated: "Our FY '24 focus...

InVitro International Reports Positive First Half and Second Quarter FY '24 Results; Also Planning an OTC Markets Uplisting

Thu, 02 May 2024 09:00:00 -0400

Placentia, California--(Newsfile Corp. - May 2, 2024) - Today, InVitro International (OTC Pink: IVRO), announced second quarter FY '24 sales of $210,615, up 5.8% compared to $199,090 for the same period FY '23. Net income in the quarter was $47,674 versus losses of $3,356 in '23. First half FY '24 sales advanced 3.4% to $422,240 versus the prior half year's $408,340. First half net income of $65,342 compared favorably (290%) to losses of $34,320 in the first half FY '23. CEO & President W....

InVitro International Sees Real Positives in Start to FY '24

Wed, 14 Feb 2024 09:00:00 -0500

Placentia, California--(Newsfile Corp. - February 14, 2024) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced first Quarter FY '24 sales ending December 31, 2023, of $211,625 up 1.1% vs. the same period in FY '23). Profits of $17,667 were ahead 157% vs. losses of $30,963 in FY' 23, same period. IVRO CEO and President, W. Richard Ulmer, stated: "It remains our intention to grow both...